Did you know? You can suggest edits to improve this peptide information.
Overview
What is FOXO4-DRI?
FOXO4-DRI (FOXO4-D-Retro-Inverso) is a synthetic 46-amino acid peptide designed to selectively eliminate senescent cells -damaged cells that accumulate with age and secrete harmful inflammatory factors (SASP). The peptide uses D-amino acids in reversed sequence, making it resistant to proteolytic degradation while maintaining binding function. FOXO4-DRI works by disrupting the FOXO4-p53 interaction that keeps senescent cells alive, causing p53 nuclear exclusion and redirecting it to mitochondria to trigger apoptosis. In mouse studies, it restored fur density, renal function, and physical fitness in aged animals while protecting against chemotherapy-induced toxicity. Notably, it shows 11.73-fold selectivity for senescent over healthy cells. No human clinical trials have been conducted; all efficacy data comes from preclinical animal and cell studies. The peptide was first described by Dr. Peter de Keizer and colleagues at Erasmus University Medical Center in 2017.
Key Benefits
Selective senescent cell elimination, tissue homeostasis restoration, potential anti-aging effects
Mechanism of Action
Disrupts FOXO4-p53 interaction in senescent cells, causing p53 nuclear exclusion. Free p53 translocates to mitochondria, triggering caspase-dependent apoptosis specifically in senescent cells while sparing healthy cells (11.73-fold selectivity demonstrated).
Molecular Information
Weight
5,358.2 Da
Length
46 amino acids (D-isoforms)
Type
D-Retro-Inverso peptide with cell-penetrating domain
Amino Acid Sequence:
H-ltlrkepaseiaqsileaysqngwanrrsggkrppprrrqrrkkrg-OH (all D-amino acids, lowercase denotes D-form)
* D-Retro-Inverso: Reversed sequence with D-amino acids. Preserves side-chain topology for receptor binding while providing protease resistance. Contains C-terminal HIV-TAT-derived cell-penetrating peptide (RRRQRRKKRG).
Pharmacokinetics
Research Indications
Senescent Cell Clearance
Selectively eliminates 'zombie' senescent cells that accumulate with age and secrete harmful inflammatory factors (SASP)
Tissue Homeostasis
Mouse studies show restoration of tissue function including fur regrowth, renal function, and physical fitness
Research Protocols
Disclaimer
FOXO4-DRI is a research compound with no human clinical data. Dosing protocols are translated from mouse studies (5 mg/kg) or derived from anecdotal self-experimentation. Human pharmacokinetics, optimal dosing, and long-term safety are completely unknown. This peptide targets the p53 tumor suppressor pathway - proceed only with full understanding of experimental nature. This is not medical advice. Consult a healthcare provider before use.
Timing
Cellular uptake within 2-4 hours, detectable for 72+ hours. D-amino acid structure provides protease resistance.
Peptide Interactions
How to Reconstitute
Important
Large D-Retro-Inverso peptide (5.3 kDa). Use sterile water or BAC water. Store lyophilized at -20°C. Gently swirl to dissolve - do not shake as protein may aggregate. Reconstituted solution at 2-8°C, use within 7-10 days.
Store lyophilized powder at -20°C until use
Allow vial to reach room temperature before reconstitution
Add sterile water slowly down vial side
Gently swirl until dissolved -do not shake (protein may denature)
Solution should be clear; discard if cloudy or precipitated
Use reconstituted solution within 7-10 days
Store reconstituted at 2-8°C
Quality Indicators
No human clinical trials
All data from mouse studies and cell culture. Human pharmacokinetics, safety, and efficacy unknown.
p53 pathway involvement
p53 is a critical tumor suppressor. Long-term effects of repeated FOXO4-p53 modulation unknown.
High synthesis cost
46 D-amino acids make production expensive. Risk of low-quality or counterfeit products.
Avoid with Rapamycin/Quercetin
May diminish senolytic effects. Require 1-2 week washout period before FOXO4-DRI administration.
High selectivity demonstrated
11.73-fold selectivity for senescent vs healthy cells in original research.
Third-party testing essential
Due to complex D-amino acid synthesis, verify peptide identity and purity via independent testing.
What to Expect
- Week 1: No reliable human timeline established
- Mouse studies: Improvements seen within 1-4 weeks
- Fur density restored in aged mice within 2-3 weeks
- Renal function normalized within study period (weeks)
- Human effects poorly characterized; proceed with caution
Side Effects & Safety
- CRITICAL: No human clinical trials -all safety data from animal studies
- Original mouse studies showed no thrombocytopenia (unlike ABT-737)
- No cardiac abnormalities on histology in mouse studies
- Does not sensitize healthy cells to DNA damage
- Anecdotal: Burning/itching at injection site reported
- Avoid concurrent use with Rapamycin, Quercetin, corticosteroids
- May not be useful for healthy individuals under 40 with low senescent cell burden
- Theoretical concern: p53 pathway critical for tumor suppression
- Unknown immunogenicity with repeated dosing
References
Targeted Apoptosis of Senescent Cells Restores Tissue Homeostasis (2017)
Landmark study introducing FOXO4-DRI. Demonstrated 11.73-fold selectivity for senescent cells. In aged mice, restored fur density, normalized renal function (plasma urea/creatinine), increased voluntary running activity, and protected against doxorubicin-induced liver damage. No thrombocytopenia or cardiac abnormalities observed.
View Study (opens in new tab) →FOXO4-DRI Alleviates Age-Related Testosterone Secretion Insufficiency (2020)
Treatment significantly increased serum testosterone levels in aged mice. Enhanced expression of testosterone synthesis enzymes (3β-HSD, CYP11A1). Decreased testicular senescence markers (p53, p21, p16) and reduced inflammatory cytokines (IL-1β, IL-6, TGF-β). No toxicity to normal Leydig cells.
View Study (opens in new tab) →Senolytic FOXO4-DRI Removes Senescent Human Chondrocytes (2021)
Removed over 50% of highly-passaged senescent chondrocytes (PDL9) while not affecting minimally-passaged cells (PDL3). Reduced senescence markers and improved cartilage quality. However, did not enhance chondrogenic potential of treated cells.
View Study (opens in new tab) →Quick Start Guide
Community Poll
Question 1 of 10
What is your experience with this compound?
Poll Results
Loading results...
Community Insights
Self-reported by PepPedia users. Not clinical evidence. Health changes reflect all users, including those taking multiple compounds.
Was this helpful?
Your feedback helps us improve PepPedia